Iterum files $20M ATM offering; ORLYNVAH launched Aug 2025 with modest sales expected

Iterum Therapeutics plc

Filed prospectus supplement for ATM offering of up to $20M aggregate gross proceeds (max ~21.8M ordinary shares).
Previously raised approximately $36.2M under same Sales Agreement with H.C. Wainwright.
ORLYNVAH commercially launched in U.S. in August 2025; company expects modest sales in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.